Formulations of hormone therapy and risk of Parkinson's disease.

@article{Lundin2014FormulationsOH,
  title={Formulations of hormone therapy and risk of Parkinson's disease.},
  author={Jessica Lundin and Thanh G. N. Ton and Andrea Z LaCroix and William T. Longstreth and Gary M. Franklin and Phillip D Swanson and Terri Smith-Weller and Brad A. Racette and Harvey Checkoway},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  year={2014},
  volume={29 13},
  pages={1631-6}
}
Hormone therapy (HT) is a class of medications widely prescribed to women in the Western world. Evidence from animal models and in vitro studies suggests that estrogen may protect against nigrostriatal system injury and increase dopamine synthesis, metabolism, and transport. Existing epidemiologic research indicates a possible reduced risk of Parkinson's disease (PD) associated with HT use. The objective of this study was to evaluate PD risk associated with specific HT formulations. Neurologist… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease

  • RA Popat, SK Van Den Eeden, CM Tanner
  • Neurology
  • 2005
Highly Influential
7 Excerpts

Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites

  • M Morissette, T. Di Paolo
  • J Neurochem 1993;60:1876-1883
  • 2014

Similar Papers

Loading similar papers…